SkelRegen Announces Addition to Management Team

SkelRegen, LLC, the leader in small molecule musculoskeletal tissue regeneration and the first to identify multiple small molecules that are osteoinductive and target different aspects of the skeletal tissue formation pathway, today announced an addition to its executive management team. Todd F. La Neve, J.D. will assume the role of [...] Read more »

SkelRegen Welcomes Director of Scientific Affairs to Management Team

SkelRegen, LLC, the leader in small molecule musculoskeletal tissue regeneration and the first to identify multiple small molecules that are osteoinductive and target different aspects of the musculoskeletal tissue formation pathway, today announced the hire of John M. Wozney, Ph.D. as Director of Scientific Affairs and Co-Owner. Read more »

SkelRegen Continues to Gain Traction in Musculoskeletal Tissue Regeneration

SkelRegen Co-Founder and Chief Medical, Science & Technology Officer; and Chief Medical Officer and Director of the Emory University Orthopaedic & Spine Hospital and Professor of Orthopaedics, Emory University School of Medicine, Scott D. Boden, MD, was part of a recent groundbreaking investigation Read more »

SkelRegen Participates in Association Annual Meeting

SkelRegen, LLC (short for Skeletal Regeneration), recently attended and participated in the National American Spine Society (NASS) annual meeting and conference in Dallas, TX. “During the meetings we had the opportunity to talk with dozens of organizations including broad, traditional orthopedic and spine companies Read more »

SkelRegen Attends 2012 OTA Meeting

The Orthopaedic Trauma Association (OTA) held its annual meeting this year from October 3 – 6 in Minneapolis, MN and SkelRegen, LLC participated in the meeting. Stephen LaNeve, SkelRegen’s CEO, said the OTA meeting represents an outstanding opportunity to network with leading orthopaedic and pharmaceutical companies Read more »

SkelRegen Aims to Regenerate Skeletal Tissue

SkelRegen-vector thumb

A new approach to musculoskeletal care appears to be on the horizon with the recent formation of a company aiming to regenerate human bone and other skeletal tissue.  The company, called SkelRegen, LLC (short for Skeletal Regeneration), has already identified several compounds that it believes could transform musculoskeletal care. Read more »

Bone Fractures, a $17B Market and Growing

It’s estimated there are over 2 million fractures costing $17 billion per year in the United States. By 2025, annual fractures and costs are projected to increase by 50% and $25 billion, respectively. Imagine the amount of time Americans suffering a fracture will spend in casts or otherwise immobilized. How [...] Read more »

Making bone is as easy as BMP (not ABC)

Whenever your body makes bone (in utero, repairing a broken bone, or healing a surgical bone fusion) it only happens when special proteins called Bone Morphogenetic Proteins (BMPs) are present. Of the tens of thousands of proteins known to man, only a select few of the BMPs are capable of [...] Read more »